Bifidobacterium adolescentis AGE17 for promoting growth and development of muscles and bones and application of bifidobacterium adolescentis AGE17

Abstract

The invention relates to the technical field of microorganisms, and particularly discloses bifidobacterium adolescentis AGE17 capable of promoting growth and development of muscles and bones and application of the bifidobacterium adolescentis AGE17. The bifidobacterium adolescentis AGE17 is separated from excrement of healthy children and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.33452, and the preservation date is January 17, 2025. The bifidobacterium adolescentis AGE17 has the advantages that the bifidobacterium adolescentis AGE17 can be used for preparing the biological organic fertilizer; animal experiments prove that the bifidobacterium adolescentis strain AGE17 provided by the invention has the function of promoting muscle and skeletal development, has more obvious and prominent effects compared with a model strain bifidobacterium adolescentis ATCC15703, and has important application value in increasing the muscle strength and height of children and adolescents.

Description

Technical Field

[0001] The present invention relates to the technical field of microorganisms, and in particular to a strain of Bifidobacterium adolescentis AGE17 for promoting muscle and bone growth and development and an application thereof. Background Art

[0002] Current interventions for child / adolescent development mainly rely on hormones or nutritional supplements (such as calcium and protein), which carry the risk of side effects (such as precocious puberty) or low absorption efficiency.

[0003] Compared to existing nutritional supplements, probiotics offer numerous advantages in promoting physical development. During the developmental stages of children and adolescents, scientifically administered probiotic supplementation can better help build a healthy bacterial barrier, strengthen the immune system, improve nutrient absorption, and ensure healthy growth.

[0004] Existing research on the functions of Bifidobacterium adolescentis primarily focuses on improving aging. For example, Bifidobacterium adolescentis ATCC15703 can extend lifespan and mitigate sarcopenia associated with aging (Zeng Zhang, 2025). Soluble polysaccharides from Bifidobacterium adolescentis ATCC15703 can combat intestinal aging (CN116870037B). Bifidobacterium adolescentis also has been shown to improve osteoporosis, a common complication of aging (CN119955658A). However, it is unclear whether Bifidobacterium adolescentis can promote development in children and adolescents. Summary of the Invention

[0005] In order to solve the problems existing in the prior art, the purpose of the present invention is to provide a strain of Bifidobacterium adolescentis that can promote muscle and bone development in children and adolescents, providing a new nutritional solution for the growth and development of children and adolescents.

[0006] In order to achieve the purpose of the present invention, the technical solution of the present invention is as follows:

[0007] In a first aspect, the present invention provides a strain of Bifidobacterium adolescentis ( Bifidobacterium adolescentis ) AGE17, the Bifidobacterium adolescentis ( Bifidobacterium adolescentis )AGE17 was deposited in the General Microbiology Center of China Culture Collection Administration of Microorganisms with the deposit number CGMCC No. 33452 and the deposit date of January 17, 2025.

[0008] The Bifidobacterium adolescentis AGE17 can tolerate gastric juice and intestinal juice in the digestive tract and has the potential to be developed into edible probiotics.

[0009] In a second aspect, the present invention provides a composition containing the Bifidobacterium adolescentis AGE17.

[0010] Furthermore, the composition is a microbial preparation, and the number of viable bacteria of Bifidobacterium adolescentis AGE17 in the microbial preparation is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g, or the cell count is not less than 1×10 9 In other words, the composition may contain live and / or inactivated bacteria of Bifidobacterium adolescentis AGE17. When live bacteria are present, the number of live bacteria is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g; when containing inactivated bacteria, the cell count is not less than 1×10 9 pcs / g.

[0011] In a third aspect, the present invention provides a product containing the Bifidobacterium adolescentis AGE17.

[0012] Furthermore, the product is a medicine, food or health product, and the product form includes but is not limited to tablets, powders and liquid preparations.

[0013] The product may also contain live and / or inactivated bacteria of Bifidobacterium adolescentis AGE17.

[0014] In a fourth aspect, the present invention provides the use of Bifidobacterium adolescentis AGE17 in promoting muscle growth and development.

[0015] In a fifth aspect, the present invention provides the use of Bifidobacterium adolescentis AGE17 in promoting bone growth and development.

[0016] In a sixth aspect, the present invention provides the use of the Bifidobacterium adolescentis AGE17 in the preparation of medicines, foods or health products for promoting muscle growth and development.

[0017] In a seventh aspect, the present invention provides the use of the Bifidobacterium adolescentis AGE17 in the preparation of medicines, foods or health products for promoting bone growth and development.

[0018] Furthermore, the above-mentioned promotion of muscle growth and development is specifically manifested in increasing the thickness of the muscle layer and muscle weight, while not excluding positive effects on aspects such as thickening of muscle fibers.

[0019] Furthermore, animal experiments using model organisms and mice have demonstrated that the Bifidobacterium adolescentis AGE17 provided by the present invention can significantly promote muscle and bone growth and development in growing organisms. Therefore, the above application is preferably targeted at growing children or adolescents.

[0020] The beneficial effects of the present invention are:

[0021] The present invention isolates and provides a strain of Bifidobacterium adolescentis, strain AGE17, which has been shown in animal experiments to promote muscle and bone development, with more pronounced and prominent effects compared to the model strain Bifidobacterium adolescentis ATCC15703. This strain has important applications for increasing muscle strength and height in children and adolescents, specifically in the preparation of medicines, foods, and health products that promote muscle and bone development in children and adolescents using Bifidobacterium adolescentis strain AGE17. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the invention and, together with the description, serve to explain the principles of the invention.

[0023] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0024] Figure 1 This is a single colony morphology of Bifidobacterium adolescentis AGE17.

[0025] Figure 2 This is a Gram staining microscopic photograph of Bifidobacterium adolescentis AGE17.

[0026] Figure 3 These are fluorescent staining images of the body wall muscles of Caenorhabditis elegans at different time points in Example 3. DETAILED DESCRIPTION

[0027] In order to more clearly understand the above-mentioned objects, features and advantages of the present invention, the solutions of the present invention will be further described below.

[0028] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein; it is obvious that the embodiments in the specification are only part of the embodiments of the present invention, rather than all the embodiments.

[0029] The preferred embodiments of the present invention will be described in detail below with reference to the examples. It should be understood that the following examples are provided for illustrative purposes only and are not intended to limit the scope of the present invention. Those skilled in the art may make various modifications and substitutions to the present invention without departing from the purpose and spirit of the present invention.

[0030] The bifidobacterium culture medium used in the following examples was purchased from Qingdao Haibo Biological through commercial channels, and its components were (g / L): trypticase peptone 5.0; soy peptone 5.0; yeast extract powder 10.0; glucose 10.0; L-cysteine ​​0.5; resazurin 0.001; potassium dihydrogen phosphate 0.04; dipotassium hydrogen phosphate 0.04; sodium bicarbonate 0.4; sodium chloride 0.08; calcium chloride 0.008; magnesium sulfate 0.0192; agar 15.0; pH 7.0.

[0031] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0032] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0033] Example 1 Origin, Isolation and Identification of Bifidobacterium adolescentis AGE17

[0034] The Bifidobacterium adolescentis AGE17 of the present invention was isolated from the feces of healthy children and was deposited in the General Microbiology Center of the China Culture Collection Administration (address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing) on ​​January 17, 2025, with the deposit number CGMCC No. 33452.

[0035] The isolation procedure is as follows: 1g of fecal sample from a healthy child is added to 5mL of Bifidobacterium culture medium and anaerobically enriched at 37°C for 24 hours. The enriched culture is diluted with a sterile 1x PBS solution. 100μL of the dilution is spread onto a Bifidobacterium agar plate. The plate is placed in an anaerobic box, tightly covered, and incubated at 37°C for 72 hours. The round, convex white colonies that grow on the plate are selected and inoculated into Bifidobacterium culture medium and anaerobically incubated at 37°C for 48 hours. An equal volume of 50% glycerol is added to the culture medium to preserve the seed.

[0036] The bacterial culture fluid remaining from the seed preservation step was taken and used as a template for PCR amplification using 16S universal primers 27F / 1492R. The amplified product was sent to a sequencing company for sequencing. The sequence is shown in SEQ ID No. 1.

[0037] The sequencing results were submitted to the NCBI database for online comparison, and the comparison results were Bifidobacterium adolescentis ( Bifidobacterium adolescentis ), and the strain was named Bifidobacterium adolescentis AGE17 ( Bifidobacterium of a young man AGE17).

[0038] The culture medium of Bifidobacterium adolescentis AGE17 was diluted and plated, and then cultured anaerobically for 48 hours. The colony morphology of Bifidobacterium adolescentis AGE17 on the Bifidobacterium agar plate was: white, smooth, convex in the middle, with complete edges and shiny round colonies ( Figure 1 ).

[0039] Take the bacterial liquid of Bifidobacterium adolescentis AGE17, evenly and thinly spread it on the slide, and observe it with an oil microscope after Gram staining. Figure 2 Shown: Gram staining of Bifidobacterium adolescentis AGE17 is positive, the bacteria are short rod-shaped, arranged singly or in pairs, without spores and flagella.

[0040] Example 2 Evaluation of the gastrointestinal survival ability of Bifidobacterium adolescentis AGE17

[0041] In order to compare and evaluate the survival ability of Bifidobacterium adolescentis AGE17 in the gastrointestinal tract, the model strain Bifidobacterium adolescentis ATCC15703 was selected as the control strain for culture tests in simulated gastric fluid and simulated intestinal fluid.

[0042] Bifidobacterium adolescentis AGE17 and Bifidobacterium adolescentis ATCC15703 were inoculated into bifidobacterium culture medium and cultured for 24 hours. The cultured bacteria were collected by centrifugation, washed with sterile PBS, and resuspended in artificial simulated gastric fluid and artificial simulated intestinal fluid respectively. The dilution plates were then spread to determine the bacterial viability at 0 hours.

[0043] After 2 hours of anaerobic static incubation at 37°C, the cells were diluted and plated for viable counts, as shown in Table 1. After 2 hours of incubation in artificial simulated gastric fluid, the survival rates of Bifidobacterium adolescentis ATCC15703 and Bifidobacterium adolescentis AGE17 were 34.8% and 74.8%, respectively. After 2 hours of incubation in artificial simulated intestinal fluid, the survival rates of Bifidobacterium adolescentis ATCC15703 and Bifidobacterium adolescentis AGE17 were 26.2% and 63.4%, respectively.

[0044] The above results show that compared with Bifidobacterium adolescentis ATCC15703, Bifidobacterium adolescentis AGE17 has a stronger ability to tolerate gastric juice and intestinal juice, and can show a higher survival rate in the gastrointestinal tract.

[0045] Table 1 Comparative test results of gastrointestinal survivability

[0046] Example 3 Bifidobacterium adolescentis AGE17 promotes the growth and development of Caenorhabditis elegans

[0047] Caenorhabditis elegans is a biological model widely used to study growth and development. Its body wall muscles are similar to vertebrate skeletal muscles in function and structure.

[0048] The present invention uses the Caenorhabditis elegans N2 strain as a research object to test the effect of Bifidobacterium adolescentis AGE17 on the growth and development of nematodes, and the control strain is the model strain Bifidobacterium adolescentis ATCC15703.

[0049] 1. Use LB medium to culture E. coli OP50 to an OD600 of 1.0, and then add it dropwise to the prepared NGM solid plate. After overnight culture at 37°C, collect the NGM solid plate for C. elegans culture.

[0050] The culture medium for Caenorhabditis elegans was NGM solid medium, and the culture temperature was 20°C.

[0051] The NGM solid culture medium was prepared as follows: 2.5 g of peptone, 3 g of sodium chloride, 17 g of agar, and 950 g of deionized water were weighed, sterilized by high-pressure steam sterilization at 121°C for 20 minutes, cooled to 55°C, and then 1 mL of 1 mol / L calcium chloride, 1 mL of 1 mol / L magnesium sulfate, 1 mL of 5 mg / mL calcium chloride, and 25 mL of 1 mol / L phosphate buffer were added. The mixture was then poured into a sterile 60 mm plastic culture dish and allowed to solidify.

[0052] 2. Synchronize C. elegans using the lysis method: Collect nematodes and add 500 μL of lysis buffer for 4 minutes. Quickly add 500 μL of M9 buffer and centrifuge at 500 g for 1 minute. Remove the supernatant and wash the pellet three times with 1 mL of M9 buffer. After washing, resuspend C. elegans eggs in an appropriate amount of M9 buffer. Plate the eggs onto NGM solid plates without E. coli OP50 and incubate at 20°C for 16 hours to obtain synchronized L1 nematodes.

[0053] The formula of the nematode lysis solution is: 2 mL of 4% sodium hypochlorite solution; 2 mL of 2.5 mol / L sodium hydroxide solution; and 6 mL of sterile water.

[0054] The formula of the M9 buffer solution is (g / L): 3g of potassium dihydrogen phosphate; 6g of disodium hydrogen phosphate; 5g of sodium chloride; and 0.12g of magnesium sulfate.

[0055] 3. Prepare NGM plates with different strains:

[0056] (1) Blank group: Add 100 μL of Escherichia coli OP50 bacterial solution to the NGM solid plate and culture at 37°C overnight.

[0057] (2) Control bacteria group: take 1 mL of a 5×10 8 CFU / mL of Bifidobacterium adolescentis ATCC15703 bacterial liquid was heat-inactivated at 100°C for 30 minutes, centrifuged at 12,000 g for 1 minute, and the supernatant was removed. After resuspending with 1 mL of Escherichia coli OP50 bacterial liquid, 100 μL was added dropwise to an NGM solid plate and cultured at 37°C overnight.

[0058] (3) AGE17 group: 1 mL of the solution was taken with a concentration of 5×10 8 CFU / mL of Bifidobacterium adolescentis AGE17 bacterial liquid was heat-inactivated at 100°C for 30 minutes, centrifuged at 12,000 g for 1 minute, and the supernatant was removed. After resuspending with 1 mL of Escherichia coli OP50 bacterial liquid, 100 μL was added dropwise to an NGM solid plate and cultured at 37°C overnight.

[0059] 4. Inoculate synchronized L1 nematodes onto NGM solid plates for the blank, control, and AGE17 groups, with 150 nematodes per plate. Incubate in a 20°C incubator. Collect nematodes from each plate at 24, 48, and 72 hours and stain with rhodamine-phalloidin.

[0060] The staining procedure is as follows: Add 100 μL of acetone to the EP tube containing the collected nematodes and let it stand at room temperature for 5 minutes. Centrifuge at 500 g for 30 seconds, then aspirate to remove as much acetone as possible. After allowing the remaining acetone to evaporate, add 100 μL of a 1:200 dilution of rhodamine-phalloidin staining solution and let it stand in the dark for 30 minutes. Centrifuge to remove the staining solution, wash three times with M9 buffer, and then transfer the nematodes to a glass slide. After removing the solution from the slide, add 20 μL of anti-fluorescence quenching mounting solution containing DAPI. Gently cover with a coverslip and let it stand in the dark until the mounting solution solidifies. Observe the fluorescently labeled nematode body wall muscles using a fluorescence microscope.

[0061] from Figure 3 As can be seen, after 24 hours of incubation, all three groups of nematodes showed red fluorescence on their body surfaces, with no fluorescent signal on the inner body wall. After 48 hours of incubation, the inner muscle layer of the nematodes in the blank and control groups was very thin, while the inner muscle layer of the AGE17 group was thicker, with bundles of muscle and distinct linear muscle fibers. After 72 hours of incubation, all three groups had developed into adults, with bundles of muscle formed on the inner body wall. However, the muscle layer of the AGE17 group was still thicker than that of the other two groups. This indicates that heat-killed B. adolescentis AGE17 can promote muscle growth in C. elegans.

[0062] After observing the fluorescence, the slides were placed under a standard optical microscope. Images were taken and the nematode lengths were measured using ImageJ software. The statistical results are shown in Table 2. At 48 hours, the worms in the AGE17 group were 4.03% longer and 9.12% longer than those in the blank and control groups, respectively. At 72 hours, the worms in the AGE17 group were 11.96% longer and 14.50% longer than those in the blank and control groups, respectively, indicating that heat-killed Bifidobacterium adolescentis AGE17 promoted nematode growth.

[0063] Table 2 Statistics of Caenorhabditis elegans worm length at different time points

[0064] The data in the table are mean ± SD. a, indicates significant difference compared with the blank group; b, indicates significant difference compared with the control group (P value less than 0.05).

[0065] Example 4 Bifidobacterium adolescentis AGE17 improves muscle strength in mice

[0066] Twenty-four male C57 mice were divided into three groups: a blank group, a control group, and an AGE17 group. The three groups of mice were gavaged from day 15 for a four-week intervention period (equivalent to childhood to mid-adolescence in humans). The AGE17 group and the control group were gavaged daily with 1×10 9 CFU of Bifidobacterium adolescentis AGE17 and the control strain ATCC15703 were administered orally. A blank control group was gavaged with an equal volume of saline. Sixteen hours after the last gavage, the mice were tested for muscle strength.

[0067] Grip strength test: Place the mouse on a grip board connected to a tester. Once the mouse is firmly planted on the board, gently grasp the base of the mouse's tail and pull horizontally at a constant speed until the mouse releases the grip board. Record the maximum pull force on the tester.

[0068] 2. Rotarod Stay Time Test: Half an hour after the grip strength test, perform the balance rotarod test. Place the mouse on the rotarod facing the direction opposite to the rod's rotation. Initially, the rotarod rotates at 4 rpm. Once the mouse has stabilized, the rotarod is accelerated uniformly, reaching 40 rpm over 300 seconds. The time it takes for the mouse to fall from the rotarod is recorded.

[0069] As can be seen from Table 3, the grip strength of mice in the AGE17 group was 17.51% and 9.93% higher than that in the blank group and the control bacteria group, respectively, and the rotarod residence time was increased by 20.33% and 17.41% compared with the blank group and the control bacteria group, respectively, indicating that oral administration of Bifidobacterium adolescentis AGE17 during the growth period of mice increased the muscle strength of mice.

[0070] Table 3 Mouse muscle strength test

[0071] The data in the table are mean ± SD. a, indicates significant difference compared with the blank group; b, indicates significant difference compared with the control group (P value less than 0.05).

[0072] Example 5 Bifidobacterium adolescentis AGE17 promotes muscle and bone development in mice

[0073] This example aims to detect muscle and bone development-related indicators in each group of mice after completing the test in Example 4.

[0074] The aforementioned mice were placed on a bone density examination bed and analyzed by X-ray scanning. The whole-body scanning mode was selected to record the bone density of each group of mice.

[0075] After recording the mouse's body weight, eye bleeding and dissection were performed. The mice were dissected, and the quadriceps, tibialis anterior, and gastrocnemius muscles were isolated and weighed. Muscle percentage was calculated (muscle percentage = muscle weight divided by body weight). The femur and tibia were removed, and their lengths were measured using a vernier caliper. The demuscularized femur and tibia were defatted by soaking in anhydrous ether for 12 hours, then placed in a 105°C oven for 72 hours. After equilibration at room temperature for 24 hours, the mouse bone weight was weighed. Bone index was calculated (bone index = defatted bone weight divided by bone length). Serum was isolated, and serum calcium, insulin-like growth factor 1 (IGF-1), and osteocalcin (OCN) levels were measured according to the kit instructions.

[0076] As can be seen from Table 4, oral administration of Bifidobacterium adolescentis AGE17 during the growth period of mice increased the weight of the quadriceps femoris, tibialis anterior and gastrocnemius muscles. The muscle proportion of the three muscles of mice in the AGE17 group was higher than that in the blank group and the control bacteria group, indicating that Bifidobacterium adolescentis AGE17 promoted muscle growth in mice.

[0077] Table 4 Mouse muscle measurement results

[0078] The data in the table are mean ± SD. a, indicates significant difference compared with the blank group; b, indicates significant difference compared with the control group (P value less than 0.05).

[0079] As can be seen from Table 5, AGE17 intervention significantly increased the length and weight of the femur and tibia, and the bone density was 12.4% higher than that of the blank group and 10.49% higher than that of the control bacteria group, indicating that AGE17 intervention promoted bone growth in mice during the growth period and made the bones of mice denser.

[0080] Sufficient serum levels of calcium, phosphorus, and other minerals promote bone mineralization. Table 5 shows that the serum calcium level in the AGE17 group was 67.20% higher than in the control group. IGF-1, the primary hormone regulating linear bone growth, was induced by AGE17 treatment, increasing its secretion by 21.64% compared to the control group. Serum osteocalcin (OCN) is a product secreted by osteoblasts during bone formation and released into the circulation. Increased levels indicate more robust bone formation during growth. Serum OCN levels were 16.15% higher in the AGE17 group compared to the control group.

[0081] These results indicate that oral administration of Bifidobacterium adolescentis AGE17 during the growth period of mice improved calcium metabolism, growth hormone secretion, osteoblast differentiation, and other methods, thereby promoting bone growth in mice.

[0082] Table 5 Analysis results of related indicators of mouse bone development

[0083] The data in the table are mean ± SD. a, indicates significant difference compared with the blank group; b, indicates significant difference compared with the control group (P value less than 0.05).

[0084] Example 6 Inactivated Bifidobacterium adolescentis AGE17 probiotic product

[0085] Centrifuge the fermentation broth of Bifidobacterium adolescentis AGE17 and collect the cells. Add 1-3 times the cell mass of a lyoprotectant (lyoprotectant w / w: 5-20% maltodextrin, 5-20% sucrose) and mix well. Heat inactivate at 100°C for 10-30 minutes. After cooling, transfer to a vacuum freeze dryer and freeze-dry. Collect the lyotropic powder, grind it, and sieve it through a 30-mesh sieve. After sieving, calculate the number of inactivated Bifidobacterium adolescentis AGE17 cells in the sample using fluorescent quantitative PCR. Add the powder to the final probiotic product. The amount of inactivated Bifidobacterium adolescentis AGE17 added to the final product is 1×10 9 to 1×10 10 pcs / g.

[0086] Example 7 Live Bacteria Bifidobacterium adolescentis AGE17 Probiotic Product

[0087] Prepared by conventional methods according to different dosage forms, the number of viable bacteria in the product is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g.

[0088] The foregoing description is intended only to provide specific embodiments of the present invention, which will enable those skilled in the art to understand and implement the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention is not intended to be limited to the embodiments described herein, but is to be construed in the widest manner consistent with the principles and novel features disclosed herein.

Claims

1. A strain of Bifidobacterium adolescentis ( Bifidobacterium adolescentis ) AGE17, characterized in that The Bifidobacterium adolescentis ( Bifidobacterium adolescentis )AGE17 was deposited in the General Microbiology Center of China Culture Collection Administration of Microorganisms with the deposit number CGMCC No. 33452 and the deposit date of January 17, 2025.

2. A composition comprising the Bifidobacterium adolescentis AGE17 according to claim 1.

3. The composition according to claim 2, characterized in that The composition is a microbial preparation, and the number of viable bacteria of Bifidobacterium adolescentis AGE17 in the microbial preparation is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g, or the cell count is not less than 1×10 9 pcs / g.

4. A product, characterized in that The product contains the Bifidobacterium adolescentis AGE17 according to claim 1.

5. The product according to claim 4, characterized in that The product is a medicine, food or health product.

6. Use of the Bifidobacterium adolescentis AGE17 according to claim 1 in promoting muscle growth and development.

7. Use of Bifidobacterium adolescentis AGE17 according to claim 1 in promoting bone growth and development.

8. Use of the Bifidobacterium adolescentis AGE17 according to claim 1 in the preparation of medicines, foods or health products for promoting muscle growth and development.

9. Use of the Bifidobacterium adolescentis AGE17 according to claim 1 in the preparation of medicines, foods or health products for promoting bone growth and development.

10. The use according to any one of claims 6 to 9, characterized in that: Promote muscle or bone growth and development in growing children or adolescents.

Images